ID   BAG1_HUMAN              Reviewed;         345 AA.
AC   Q99933; O75315; Q14414; Q53H32; Q5VZE8; Q5VZE9; Q5VZF0; Q96TG2; Q9Y2V4;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   18-MAY-2010, sequence version 4.
DT   18-JUN-2025, entry version 229.
DE   RecName: Full=BAG family molecular chaperone regulator 1;
DE            Short=BAG-1;
DE   AltName: Full=Bcl-2-associated athanogene 1;
GN   Name=BAG1; Synonyms=HAP;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=8524784; DOI=10.1073/pnas.92.25.11465;
RA   Zeiner M., Gehring U.;
RT   "A protein that interacts with members of the nuclear hormone receptor
RT   family: identification and cDNA cloning.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:11465-11469(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Mammary gland;
RX   PubMed=8812483; DOI=10.1006/geno.1996.0389;
RA   Takayama S., Kochel K., Irie S., Inazawa J., Abe T., Sato T., Druck T.,
RA   Huebner K., Reed J.C.;
RT   "Cloning of cDNAs encoding the human BAG1 protein and localization of the
RT   human BAG1 gene to chromosome 9p12.";
RL   Genomics 35:494-498(1996).
RN   [3]
RP   SEQUENCE REVISION TO N-TERMINUS; 79; 84; 90; 245 AND 293.
RA   Takayama S.;
RL   Submitted (SEP-1997) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), ANTI-APOPTOTIC ACTIVITY,
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH MAPRE2.
RC   TISSUE=T-cell;
RX   PubMed=15986447; DOI=10.1002/ijc.21259;
RA   Wadle A., Mischo A., Henrich P.P., Stenner-Lieven F., Scherer C., Imig J.,
RA   Petersen G., Pfreundschuh M., Renner C.;
RT   "Characterization of Hap/BAG-1 variants as RP1 binding proteins with
RT   antiapoptotic activity.";
RL   Int. J. Cancer 117:896-904(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Dermoid cancer;
RA   Suzuki Y., Sugano S., Totoki Y., Toyoda A., Takeda T., Sakaki Y.,
RA   Tanaka A., Yokoyama S.;
RL   Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Cervix, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [9]
RP   IDENTIFICATION OF ISOFORMS 1 AND 4, AND ALTERNATIVE INITIATION.
RX   PubMed=9396724; DOI=10.1042/bj3280807;
RA   Packham G., Brimmell M., Cleveland J.L.;
RT   "Mammalian cells express two differently localized Bag-1 isoforms generated
RT   by alternative translation initiation.";
RL   Biochem. J. 328:807-813(1997).
RN   [10]
RP   FUNCTION, SUBUNIT, AND INTERACTION WITH BCL2; HSP70 AND HSPA8.
RX   PubMed=9305631; DOI=10.1093/emboj/16.16.4887;
RA   Takayama S., Bimston D.N., Matsuzawa S.-I., Freeman B.C., Aime-Sempe C.,
RA   Xie Z., Morimoto R.I., Reed J.C.;
RT   "BAG-1 modulates the chaperone activity of Hsp70/Hsc70.";
RL   EMBO J. 16:4887-4896(1997).
RN   [11]
RP   IDENTIFICATION OF ISOFORMS 1; 3 AND 4, ALTERNATIVE INITIATION, SUBCELLULAR
RP   LOCATION, INTERACTION WITH HSPA8, INDUCTION, AND TISSUE SPECIFICITY.
RX   PubMed=9679980;
RA   Takayama S., Krajewski S., Krajewska M., Kitada S., Zapata J.M., Kochel K.,
RA   Knee D., Scudiero D., Tudor G., Miller G.J., Miyashita T., Yamada M.,
RA   Reed J.C.;
RT   "Expression and location of Hsp70/Hsc-binding anti-apoptotic protein BAG-1
RT   and its variants in normal tissues and tumor cell lines.";
RL   Cancer Res. 58:3116-3131(1998).
RN   [12]
RP   INTERACTION WITH SIAH1.
RX   PubMed=9582267; DOI=10.1093/emboj/17.10.2736;
RA   Matsuzawa S., Takayama S., Froesch B.A., Zapata J.M., Reed J.C.;
RT   "p53-inducible human homologue of Drosophila seven in absentia (Siah)
RT   inhibits cell growth: suppression by BAG-1.";
RL   EMBO J. 17:2736-2747(1998).
RN   [13]
RP   FUNCTION.
RX   PubMed=9873016; DOI=10.1074/jbc.274.2.781;
RA   Takayama S., Xie Z., Reed J.C.;
RT   "An evolutionarily conserved family of Hsp70/Hsc70 molecular chaperone
RT   regulators.";
RL   J. Biol. Chem. 274:781-786(1999).
RN   [14]
RP   INTERACTION WITH NR3C1.
RX   PubMed=10477749; DOI=10.1083/jcb.146.5.929;
RA   Schneikert J., Huebner S., Martin E., Cato A.B.C.;
RT   "A nuclear action of the eukaryotic cochaperone RAP46 in downregulation of
RT   glucocorticoid receptor activity.";
RL   J. Cell Biol. 146:929-940(1999).
RN   [15]
RP   INTERACTION WITH PPP1R15A, AND FUNCTION.
RX   PubMed=12724406; DOI=10.1128/mcb.23.10.3477-3486.2003;
RA   Hung W.J., Roberson R.S., Taft J., Wu D.Y.;
RT   "Human BAG-1 proteins bind to the cellular stress response protein GADD34
RT   and interfere with GADD34 functions.";
RL   Mol. Cell. Biol. 23:3477-3486(2003).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-223, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [18]
RP   FUNCTION, AND INTERACTION WITH HSPA1A; HSPA1B AND HSPA8.
RX   PubMed=24318877; DOI=10.1074/jbc.m113.521997;
RA   Rauch J.N., Gestwicki J.E.;
RT   "Binding of human nucleotide exchange factors to heat shock protein 70
RT   (Hsp70) generates functionally distinct complexes in vitro.";
RL   J. Biol. Chem. 289:1402-1414(2014).
RN   [19]
RP   FUNCTION, INTERACTION WITH HSPA8, AND MUTAGENESIS OF 308-ARG-LYS-309.
RX   PubMed=27474739; DOI=10.1074/jbc.m116.742502;
RA   Rauch J.N., Zuiderweg E.R., Gestwicki J.E.;
RT   "Non-canonical interactions between heat shock cognate protein 70 (Hsc70)
RT   and Bcl2-associated anthanogene (BAG) co-chaperones are important for
RT   client release.";
RL   J. Biol. Chem. 291:19848-19857(2016).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (1.9 ANGSTROMS) OF 222-334 IN COMPLEX WITH HSC70.
RX   PubMed=11222862; DOI=10.1126/science.1057268;
RA   Sondermann H., Scheufler C., Schneider C., Hohfeld J., Hartl F.U.,
RA   Moarefi I.;
RT   "Structure of a Bag/Hsc70 complex: convergent functional evolution of Hsp70
RT   nucleotide exchange factors.";
RL   Science 291:1553-1557(2001).
RN   [21]
RP   STRUCTURE BY NMR OF 143-223.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Solution structure of the ubiquitin domain of Bcl-2 binding
RT   athanogene-1.";
RL   Submitted (AUG-2005) to the PDB data bank.
CC   -!- FUNCTION: Co-chaperone for HSP70 and HSC70 chaperone proteins. Acts as
CC       a nucleotide-exchange factor (NEF) promoting the release of ADP from
CC       the HSP70 and HSC70 proteins thereby triggering client/substrate
CC       protein release. Nucleotide release is mediated via its binding to the
CC       nucleotide-binding domain (NBD) of HSPA8/HSC70 where as the substrate
CC       release is mediated via its binding to the substrate-binding domain
CC       (SBD) of HSPA8/HSC70 (PubMed:24318877, PubMed:27474739,
CC       PubMed:9873016). Inhibits the pro-apoptotic function of PPP1R15A, and
CC       has anti-apoptotic activity (PubMed:12724406). Markedly increases the
CC       anti-cell death function of BCL2 induced by various stimuli
CC       (PubMed:9305631). Involved in the STUB1-mediated proteasomal
CC       degradation of ESR1 in response to age-related circulating estradiol
CC       (17-beta-estradiol/E2) decline, thereby promotes neuronal apoptosis in
CC       response to ischemic reperfusion injury (By similarity).
CC       {ECO:0000250|UniProtKB:B0K019, ECO:0000269|PubMed:12724406,
CC       ECO:0000269|PubMed:24318877, ECO:0000269|PubMed:27474739,
CC       ECO:0000269|PubMed:9305631, ECO:0000269|PubMed:9873016}.
CC   -!- SUBUNIT: Homodimer. Forms a heteromeric complex with HSP70/HSC70
CC       (PubMed:9305631). Binds to the ATPase domain of HSP/HSC70 chaperones.
CC       Isoform 1, isoform 3 and isoform 4 but not isoform 2 interact with
CC       HSPA8/HSC70 (PubMed:24318877, PubMed:27474739, PubMed:9305631,
CC       PubMed:9679980). Interacts with NR3C1 (PubMed:10477749). Interacts with
CC       the N-terminal region of MAPRE2 (PubMed:15986447). Interacts with
CC       PPP1R15A (PubMed:12724406). Interacts with BCL2 in an ATP-dependent
CC       manner. Isoform 2 does not interact with BCL2 (PubMed:9305631).
CC       Interacts with SIAH1 (PubMed:9582267). Interacts with HSPA8 (via NBD)
CC       (PubMed:24318877, PubMed:27474739). Interacts with HSPA1A (via NBD) and
CC       HSPA1B (via NBD) (PubMed:24318877). Interacts with SIAH2 (By
CC       similarity). Interacts with ESR1; the interaction is promoted in the
CC       absence of estradiol (17-beta-estradiol/E2) (By similarity).
CC       {ECO:0000250|UniProtKB:B0K019, ECO:0000250|UniProtKB:Q60739,
CC       ECO:0000269|PubMed:10477749, ECO:0000269|PubMed:11222862,
CC       ECO:0000269|PubMed:12724406, ECO:0000269|PubMed:15986447,
CC       ECO:0000269|PubMed:24318877, ECO:0000269|PubMed:27474739,
CC       ECO:0000269|PubMed:9305631, ECO:0000269|PubMed:9582267,
CC       ECO:0000269|PubMed:9679980}.
CC   -!- INTERACTION:
CC       Q99933; P11142: HSPA8; NbExp=13; IntAct=EBI-1030678, EBI-351896;
CC       Q99933; Q96IS6: HSPA8; NbExp=5; IntAct=EBI-1030678, EBI-10289199;
CC       Q99933; Q15773: MLF2; NbExp=2; IntAct=EBI-1030678, EBI-1051875;
CC       Q99933; Q13200: PSMD2; NbExp=9; IntAct=EBI-1030678, EBI-357648;
CC       Q99933; Q9UNE7: STUB1; NbExp=2; IntAct=EBI-1030678, EBI-357085;
CC       Q99933; P36406: TRIM23; NbExp=5; IntAct=EBI-1030678, EBI-740098;
CC       Q99933; P14373: TRIM27; NbExp=7; IntAct=EBI-1030678, EBI-719493;
CC       Q99933; Q53FC7; NbExp=2; IntAct=EBI-1030678, EBI-9356749;
CC       Q99933; Q96BE0; NbExp=2; IntAct=EBI-1030678, EBI-9356686;
CC   -!- SUBCELLULAR LOCATION: [Isoform 1]: Nucleus. Cytoplasm. Note=Isoform 1
CC       localizes predominantly to the nucleus.
CC   -!- SUBCELLULAR LOCATION: [Isoform 2]: Cytoplasm. Nucleus. Note=Isoform 2
CC       localizes to the cytoplasm and shuttles into the nucleus in response to
CC       heat shock.
CC   -!- SUBCELLULAR LOCATION: [Isoform 4]: Cytoplasm. Nucleus. Note=Isoform 4
CC       localizes predominantly to the cytoplasm. The cellular background in
CC       which it is expressed can influence whether it resides primarily in the
CC       cytoplasm or is also found in the nucleus. In the presence of BCL2,
CC       localizes to intracellular membranes (what appears to be the nuclear
CC       envelope and perinuclear membranes) as well as punctate cytosolic
CC       structures suggestive of mitochondria.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing, Alternative initiation; Named isoforms=4;
CC       Name=1; Synonyms=BAG-1L, p50;
CC         IsoId=Q99933-1; Sequence=Displayed;
CC       Name=2; Synonyms=BAG1V, HAPV;
CC         IsoId=Q99933-2; Sequence=VSP_000453;
CC       Name=3; Synonyms=BAG-1M, RAP46;
CC         IsoId=Q99933-3; Sequence=VSP_038395;
CC       Name=4; Synonyms=BAG-1, p32;
CC         IsoId=Q99933-4; Sequence=VSP_038394;
CC   -!- TISSUE SPECIFICITY: Isoform 4 is the most abundantly expressed isoform.
CC       It is ubiquitously expressed throughout most tissues, except the liver,
CC       colon, breast and uterine myometrium. Isoform 1 is expressed in the
CC       ovary and testis. Isoform 4 is expressed in several types of tumor cell
CC       lines, and at consistently high levels in leukemia and lymphoma cell
CC       lines. Isoform 1 is expressed in the prostate, breast and leukemia cell
CC       lines. Isoform 3 is the least abundant isoform in tumor cell lines (at
CC       protein level). {ECO:0000269|PubMed:9679980}.
CC   -!- INDUCTION: Up-regulated during differentiation of bladder epithelial
CC       cells and down-regulated during differentiation of prostate epithelium.
CC       {ECO:0000269|PubMed:9679980}.
CC   -!- PTM: Ubiquitinated; mediated by SIAH1 or SIAH2 and leading to its
CC       subsequent proteasomal degradation. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 2]: Produced by alternative splicing.
CC       {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Produced by alternative initiation at Met-
CC       72 of isoform 1. {ECO:0000305}.
CC   -!- MISCELLANEOUS: [Isoform 4]: Produced by alternative initiation at Met-
CC       116 of isoform 1. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAD11467.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=AAD25045.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=BAD96469.1; Type=Miscellaneous discrepancy; Note=Unusual initiator. The initiator methionine is coded by a non-canonical CTG leucine codon.; Evidence={ECO:0000305};
CC       Sequence=CAA84624.1; Type=Erroneous initiation; Note=Truncated N-terminus.; Evidence={ECO:0000305};
CC       Sequence=EAW58515.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/742/BAG1";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z35491; CAA84624.1; ALT_INIT; mRNA.
DR   EMBL; U46917; AAD11467.1; ALT_INIT; mRNA.
DR   EMBL; AF022224; AAC34258.1; -; mRNA.
DR   EMBL; AF116273; AAD25045.1; ALT_INIT; mRNA.
DR   EMBL; AK222749; BAD96469.1; ALT_INIT; mRNA.
DR   EMBL; AL161445; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL356472; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471071; EAW58514.1; -; Genomic_DNA.
DR   EMBL; CH471071; EAW58515.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; BC001936; AAH01936.2; -; mRNA.
DR   EMBL; BC014774; AAH14774.2; -; mRNA.
DR   CCDS; CCDS35004.1; -. [Q99933-1]
DR   CCDS; CCDS55301.1; -. [Q99933-4]
DR   RefSeq; NP_001165886.1; NM_001172415.2. [Q99933-4]
DR   RefSeq; NP_001336215.1; NM_001349286.2. [Q99933-3]
DR   RefSeq; NP_004314.5; NM_004323.5. [Q99933-1]
DR   PDB; 1HX1; X-ray; 1.90 A; B=222-334.
DR   PDB; 1WXV; NMR; -; A=144-222.
DR   PDB; 3FZF; X-ray; 2.20 A; B=222-334.
DR   PDB; 3FZH; X-ray; 2.00 A; B=222-334.
DR   PDB; 3FZK; X-ray; 2.10 A; B=222-334.
DR   PDB; 3FZL; X-ray; 2.20 A; B=222-334.
DR   PDB; 3FZM; X-ray; 2.30 A; B=222-334.
DR   PDB; 3LDQ; X-ray; 1.90 A; B=222-334.
DR   PDB; 3M3Z; X-ray; 2.10 A; B=222-334.
DR   PDB; 5AQF; X-ray; 1.88 A; B/D=222-334.
DR   PDB; 5AQG; X-ray; 2.24 A; B/D/F=222-334.
DR   PDB; 5AQH; X-ray; 2.00 A; B=222-334.
DR   PDB; 5AQI; X-ray; 1.98 A; B/D=222-334.
DR   PDB; 5AQJ; X-ray; 1.96 A; B/D/F=222-334.
DR   PDB; 5AQK; X-ray; 2.09 A; B=222-334.
DR   PDB; 5AQL; X-ray; 1.69 A; B/D=222-334.
DR   PDB; 5AQM; X-ray; 1.63 A; B/D=222-334.
DR   PDB; 5AQN; X-ray; 2.45 A; B/D/F=222-334.
DR   PDB; 5AQO; X-ray; 2.12 A; B/D/F=222-334.
DR   PDB; 5AQP; X-ray; 2.08 A; B/D/F=222-334.
DR   PDB; 5AQQ; X-ray; 2.72 A; B/D/F=222-334.
DR   PDB; 5AQR; X-ray; 1.91 A; B/D/F=222-334.
DR   PDB; 5AQS; X-ray; 2.00 A; B/D=222-334.
DR   PDB; 5AQT; X-ray; 1.90 A; B=222-334.
DR   PDB; 5AQU; X-ray; 1.92 A; B=222-334.
DR   PDB; 5AQV; X-ray; 1.75 A; B=222-334.
DR   PDBsum; 1HX1; -.
DR   PDBsum; 1WXV; -.
DR   PDBsum; 3FZF; -.
DR   PDBsum; 3FZH; -.
DR   PDBsum; 3FZK; -.
DR   PDBsum; 3FZL; -.
DR   PDBsum; 3FZM; -.
DR   PDBsum; 3LDQ; -.
DR   PDBsum; 3M3Z; -.
DR   PDBsum; 5AQF; -.
DR   PDBsum; 5AQG; -.
DR   PDBsum; 5AQH; -.
DR   PDBsum; 5AQI; -.
DR   PDBsum; 5AQJ; -.
DR   PDBsum; 5AQK; -.
DR   PDBsum; 5AQL; -.
DR   PDBsum; 5AQM; -.
DR   PDBsum; 5AQN; -.
DR   PDBsum; 5AQO; -.
DR   PDBsum; 5AQP; -.
DR   PDBsum; 5AQQ; -.
DR   PDBsum; 5AQR; -.
DR   PDBsum; 5AQS; -.
DR   PDBsum; 5AQT; -.
DR   PDBsum; 5AQU; -.
DR   PDBsum; 5AQV; -.
DR   AlphaFoldDB; Q99933; -.
DR   SMR; Q99933; -.
DR   BioGRID; 107049; 483.
DR   CORUM; Q99933; -.
DR   DIP; DIP-3341N; -.
DR   FunCoup; Q99933; 2373.
DR   IntAct; Q99933; 127.
DR   MINT; Q99933; -.
DR   STRING; 9606.ENSP00000489189; -.
DR   DrugBank; DB07045; (2R,3R,4S,5R)-2-[6-amino-8-[(3,4-dichlorophenyl)methylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol.
DR   GlyGen; Q99933; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q99933; -.
DR   PhosphoSitePlus; Q99933; -.
DR   BioMuta; BAG1; -.
DR   DMDM; 296439462; -.
DR   jPOST; Q99933; -.
DR   MassIVE; Q99933; -.
DR   PaxDb; 9606-ENSP00000420514; -.
DR   PeptideAtlas; Q99933; -.
DR   ProteomicsDB; 78526; -. [Q99933-1]
DR   ProteomicsDB; 78527; -. [Q99933-2]
DR   ProteomicsDB; 78528; -. [Q99933-3]
DR   ProteomicsDB; 78529; -. [Q99933-4]
DR   Pumba; Q99933; -.
DR   Antibodypedia; 2968; 550 antibodies from 41 providers.
DR   DNASU; 573; -.
DR   Ensembl; ENST00000379704.7; ENSP00000369026.2; ENSG00000107262.26. [Q99933-4]
DR   Ensembl; ENST00000634734.3; ENSP00000489189.2; ENSG00000107262.26. [Q99933-1]
DR   GeneID; 573; -.
DR   KEGG; hsa:573; -.
DR   MANE-Select; ENST00000634734.3; ENSP00000489189.2; NM_004323.6; NP_004314.6.
DR   UCSC; uc064sos.1; human. [Q99933-1]
DR   AGR; HGNC:937; -.
DR   CTD; 573; -.
DR   DisGeNET; 573; -.
DR   GeneCards; BAG1; -.
DR   HGNC; HGNC:937; BAG1.
DR   HPA; ENSG00000107262; Low tissue specificity.
DR   MIM; 601497; gene.
DR   OpenTargets; ENSG00000107262; -.
DR   VEuPathDB; HostDB:ENSG00000107262; -.
DR   eggNOG; ENOG502RN5W; Eukaryota.
DR   GeneTree; ENSGT00450000040296; -.
DR   HOGENOM; CLU_055378_0_1_1; -.
DR   InParanoid; Q99933; -.
DR   OMA; HSECNEK; -.
DR   OrthoDB; 417450at2759; -.
DR   PAN-GO; Q99933; 7 GO annotations based on evolutionary models.
DR   PhylomeDB; Q99933; -.
DR   PathwayCommons; Q99933; -.
DR   Reactome; R-HSA-3371453; Regulation of HSF1-mediated heat shock response.
DR   SignaLink; Q99933; -.
DR   SIGNOR; Q99933; -.
DR   BioGRID-ORCS; 573; 14 hits in 1168 CRISPR screens.
DR   ChiTaRS; BAG1; human.
DR   EvolutionaryTrace; Q99933; -.
DR   GeneWiki; BAG1; -.
DR   GenomeRNAi; 573; -.
DR   Pharos; Q99933; Tbio.
DR   PRO; PR:Q99933; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q99933; protein.
DR   Bgee; ENSG00000107262; Expressed in palpebral conjunctiva and 213 other cell types or tissues.
DR   ExpressionAtlas; Q99933; baseline and differential.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0016020; C:membrane; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0000774; F:adenyl-nucleotide exchange factor activity; IDA:UniProtKB.
DR   GO; GO:0051087; F:protein-folding chaperone binding; IBA:GO_Central.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:ARUK-UCL.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; TAS:ProtInc.
DR   GO; GO:0051085; P:chaperone cofactor-dependent protein refolding; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc.
DR   GO; GO:0034393; P:positive regulation of smooth muscle cell apoptotic process; ISS:UniProtKB.
DR   GO; GO:0050821; P:protein stabilization; IBA:GO_Central.
DR   CDD; cd01812; Ubl_BAG1; 1.
DR   FunFam; 1.20.58.120:FF:000005; BAG family molecular chaperone regulator 1; 1.
DR   FunFam; 3.10.20.90:FF:000237; BAG family molecular chaperone regulator 1; 1.
DR   Gene3D; 1.20.58.120; BAG domain; 1.
DR   Gene3D; 3.10.20.90; Phosphatidylinositol 3-kinase Catalytic Subunit, Chain A, domain 1; 1.
DR   IDEAL; IID00495; -.
DR   InterPro; IPR039773; BAG_chaperone_regulator.
DR   InterPro; IPR036533; BAG_dom_sf.
DR   InterPro; IPR003103; BAG_domain.
DR   InterPro; IPR000626; Ubiquitin-like_dom.
DR   InterPro; IPR029071; Ubiquitin-like_domsf.
DR   PANTHER; PTHR12329:SF16; BAG FAMILY MOLECULAR CHAPERONE REGULATOR 1; 1.
DR   PANTHER; PTHR12329; BCL2-ASSOCIATED ATHANOGENE; 1.
DR   Pfam; PF02179; BAG; 1.
DR   Pfam; PF00240; ubiquitin; 1.
DR   SMART; SM00264; BAG; 1.
DR   SMART; SM00213; UBQ; 1.
DR   SUPFAM; SSF63491; BAG domain; 1.
DR   SUPFAM; SSF54236; Ubiquitin-like; 1.
DR   PROSITE; PS51035; BAG; 1.
DR   PROSITE; PS50053; UBIQUITIN_2; 1.
DR   neXtProt; NX_Q99933; -.
DR   PharmGKB; PA25237; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative initiation; Alternative splicing; Apoptosis;
KW   Chaperone; Cytoplasm; Nucleus; Phosphoprotein; Proteomics identification;
KW   Reference proteome; Repeat; Ubl conjugation.
FT   CHAIN           1..345
FT                   /note="BAG family molecular chaperone regulator 1"
FT                   /id="PRO_0000088865"
FT   REPEAT          96..101
FT                   /note="1"
FT   REPEAT          102..107
FT                   /note="2"
FT   REPEAT          108..113
FT                   /note="3"
FT   REPEAT          114..119
FT                   /note="4"
FT   REPEAT          120..125
FT                   /note="5"
FT   REPEAT          126..131
FT                   /note="6"
FT   REPEAT          132..137
FT                   /note="7"
FT   DOMAIN          144..224
FT                   /note="Ubiquitin-like"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00214"
FT   DOMAIN          246..326
FT                   /note="BAG"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00369"
FT   REGION          1..137
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          96..137
FT                   /note="7 X 6 AA tandem repeat of E-E-X(4)"
FT   REGION          172..219
FT                   /note="Interaction with HSPA8"
FT   REGION          216..345
FT                   /note="Interaction with PPP1R15A"
FT                   /evidence="ECO:0000269|PubMed:12724406"
FT   COMPBIAS        68..80
FT                   /note="Basic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        81..91
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        95..114
FT                   /note="Low complexity"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        115..137
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         223
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   VAR_SEQ         1..115
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_038394"
FT   VAR_SEQ         1..71
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000305"
FT                   /id="VSP_038395"
FT   VAR_SEQ         302..345
FT                   /note="KDSRLKRKGLVKKVQAFLAECDTVEQNICQETERLQSTNFALAE -> PTLT
FT                   LVLNEK (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15986447"
FT                   /id="VSP_000453"
FT   MUTAGEN         308..309
FT                   /note="RK->AA: Significant loss of interaction with HSPA8."
FT                   /evidence="ECO:0000269|PubMed:27474739"
FT   CONFLICT        45
FT                   /note="G -> R (in Ref. 2; AAC34258, 5; BAD96469 and 8;
FT                   AAH01936/AAH14774)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        79
FT                   /note="R -> F (in Ref. 2; AAD11467)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        84
FT                   /note="E -> K (in Ref. 2; AAD11467)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        90
FT                   /note="E -> K (in Ref. 2; AAD11467)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        245
FT                   /note="D -> N (in Ref. 2; AAD11467)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        293
FT                   /note="D -> H (in Ref. 2; AAD11467)"
FT                   /evidence="ECO:0000305"
FT   STRAND          144..149
FT                   /evidence="ECO:0007829|PDB:1WXV"
FT   STRAND          151..159
FT                   /evidence="ECO:0007829|PDB:1WXV"
FT   STRAND          163..167
FT                   /evidence="ECO:0007829|PDB:1WXV"
FT   HELIX           170..180
FT                   /evidence="ECO:0007829|PDB:1WXV"
FT   TURN            185..187
FT                   /evidence="ECO:0007829|PDB:1WXV"
FT   STRAND          189..192
FT                   /evidence="ECO:0007829|PDB:1WXV"
FT   STRAND          195..197
FT                   /evidence="ECO:0007829|PDB:1WXV"
FT   STRAND          200..203
FT                   /evidence="ECO:0007829|PDB:1WXV"
FT   HELIX           204..207
FT                   /evidence="ECO:0007829|PDB:1WXV"
FT   STRAND          211..219
FT                   /evidence="ECO:0007829|PDB:1WXV"
FT   HELIX           224..259
FT                   /evidence="ECO:0007829|PDB:5AQM"
FT   STRAND          260..262
FT                   /evidence="ECO:0007829|PDB:5AQR"
FT   HELIX           264..272
FT                   /evidence="ECO:0007829|PDB:5AQM"
FT   HELIX           275..292
FT                   /evidence="ECO:0007829|PDB:5AQM"
FT   HELIX           302..327
FT                   /evidence="ECO:0007829|PDB:5AQM"
SQ   SEQUENCE   345 AA;  38779 MW;  8B40EF078C66335F CRC64;
     MAQRGGARRP RGDRERLGSR LRALRPGREP RQSEPPAQRG PPPSGRPPAR STASGHDRPT
     RGAAAGARRP RMKKKTRRRS TRSEELTRSE ELTLSEEATW SEEATQSEEA TQGEEMNRSQ
     EVTRDEESTR SEEVTREEMA AAGLTVTVTH SNEKHDLHVT SQQGSSEPVV QDLAQVVEEV
     IGVPQSFQKL IFKGKSLKEM ETPLSALGIQ DGCRVMLIGK KNSPQEEVEL KKLKHLEKSV
     EKIADQLEEL NKELTGIQQG FLPKDLQAEA LCKLDRRVKA TIEQFMKILE EIDTLILPEN
     FKDSRLKRKG LVKKVQAFLA ECDTVEQNIC QETERLQSTN FALAE
//
